CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO AMENDED AND RESTATED...Distribution Agreement • August 17th, 2020 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO AMENDED AND RESTATED DISTRIBUTION, DEVELOPMENT, COMMERCIALIZATION & SUPPLY AGREEMENT (this “Amendment”), is entered into and effective as of February 19, 2020 (the “Amendment Effective Date”), by and between US WorldMeds, LLC, a Delaware limited liability company with its principle place of business at 4441 Springdale Road, Louisville, KY 40241 (“USWM”), and Britannia Pharmaceuticals Limited, whose registered office is at Park View House, 65, London Road, Newbury, Berkshire RG14 1JN (“BPL” or “Britannia”). Each of USWM and BPL may be referred to individually herein as a “Party” and, collectively, as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED DISTRIBUTION,...Distribution, Development, Commercialization & Supply Agreement • August 17th, 2020 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CONFIDENTIAL DATED April 28, 2020 US WORLDMEDS PARTNERS, LLC (on behalf of the Company Group) and SUPERNUS PHARMACEUTICALS, INC. SALE AND PURCHASE AGREEMENT RELATING TO USWM ENTERPRISES, LLCSale and Purchase Agreement • August 17th, 2020 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Private and Confidential Dated April...Development and Option Agreement • August 17th, 2020 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), effective as of April 21, 2020 (the “Effective Date”), is entered into by and between NAVITOR PHARMACEUTICALS, INC., a company registered under the laws of the state of Delaware having offices at 1030 Massachusetts Avenue, Suite 410, Cambridge, MA 02138 (“Navitor”) and SUPERNUS PHARMACEUTICALS, INC., a corporation registered under the laws of the state of Delaware having offices at 9715 Key West Avenue, Rockville, MD 20850 (“Supernus”).
